| Acrow Limited (ACF) ORDINARY FULLY PAID |
Industrials |
$309 |
Dividend/Distribution - ACF
|
25 Aug 2025 6:54PM |
$1.050 |
$0.880 |
fallen by
16.19%
|
|
| Acrow Limited (ACF) ORDINARY FULLY PAID |
Industrials |
$309 |
Appendix 4E - Preliminary Final Report
|
25 Aug 2025 6:49PM |
$1.050 |
$0.880 |
fallen by
16.19%
|
|
ACF - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue from continuing operations was $241.66 million.
- Net finance costs increased to $10.2 million.
- Profit before income tax was $34.83 million.
- Income tax expense was $11.56 million.
- Net profit after tax was $23.27 million.
- Shareholder equity totaled $149.09 million.
- Issued capital amounted to $93.75 million.
- Dividends of 5.85 cents per share were maintained and fully franked.
- Significant items impacted the net profit.
- Total assets increased to $406.14 million.
- Borrowings increased due to acquisitions and capital expenditures.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Acrow Limited (ACF) ORDINARY FULLY PAID |
Industrials |
$309 |
Appendix 4E - Preliminary Final Report
|
25 Aug 2025 6:49PM |
$1.050 |
$0.880 |
fallen by
16.19%
|
|
ACF - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 23% year-on-year, reaching $265.1 million.
- Underlying EBITDA rose by 8% to $80.2 million.
- Net profit after tax increased by 4% to $34.3 million.
- Earnings per share decreased slightly by 3% due to increased shares.
- Dividends remained at 5.85 cents per share, fully franked.
- Significant acquisitions included Acrow Energy and Infrastructure Services.
- Net debt increased due to acquisitions and growth capital expenditure.
- Formwork and Commercial Scaffold divisions experienced declines in revenue.
- The report is based on audited financial statements by Grant Thornton.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Activeport Group Ltd (ATV) ORDINARY FULLY PAID |
Information Technology |
$26 |
ATV Completion of pro-rata entitlement issue
|
25 Aug 2025 6:48PM |
$0.019 |
$0.023 |
risen by
21.05%
|
|
ATV - Price-sensitive ASX Announcement
Full Release
Key Points
- Non-renounceable rights issue successfully completed.
- Rights issue aimed to raise approximately $2.5 million.
- Offer set at 1 cent per share, fully underwritten.
- Eligible shareholders received 1 free option for every 2 new shares.
- 180,660,857 new shares subscribed, 72% take-up.
- 153,305,152 shares subscribed via shortfall applications.
- Alpine Capital Pty Ltd and GBA Capital Pty Ltd were Joint Lead Managers and Underwriters.
- New securities issued on 29 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Activeport Group Ltd (ATV) ORDINARY FULLY PAID |
Information Technology |
$26 |
ATV Completion of pro-rata entitlement issue
|
25 Aug 2025 6:48PM |
$0.019 |
$0.023 |
risen by
21.05%
|
|
ATV - Price-sensitive ASX Announcement
Full Release
Key Points
- Activeport Group Ltd announced the successful completion of its entitlement offer.
- The non-renounceable rights issue was announced on 4 August 2025 and closed on 22 August 2025.
- The 1 for 2.75 rights issue was priced at 1 cent per share to raise approximately $2.5 million.
- For every 2 new shares issued, eligible shareholders receive 1 free attaching new option.
- The new options have an exercise price of 2 cents and expire on 30 November 2028.
- The rights issue was fully underwritten by Alpine Capital Pty Ltd and GBA Capital Pty Ltd.
- New securities are scheduled to be issued on 29 August 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
Appendix 4G
|
25 Aug 2025 6:47PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
Corporate Governance Statement
|
25 Aug 2025 6:46PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
ACW FY2025 results - accelerating Alzheimers pivotal trial
|
25 Aug 2025 6:46PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen released its FY2025 financial results.
- XanaMIA Phase 2b/3 Alzheimer’s trial reached 100 participants.
- Interim analysis of XanaMIA expected in January 2026.
- XanaCIDD Phase 2a depression trial showed significant benefits.
- Actinogen received $11.1m capital raising and $9m R&D tax rebate.
- Preparation for commercialization and regulatory discussions ongoing.
- A 15kg batch of Xanamem tablets produced for trials.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
ACW FY2025 results - accelerating Alzheimers pivotal trial
|
25 Aug 2025 6:46PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited (ACW) released its FY2025 financial results, highlighting progress toward pivotal trial results for Alzheimer's disease.
- The XanaMIA Phase 2b/3 clinical trial for Alzheimer's disease surpassed the 100th participant milestone, with interim analysis in January 2026 and final results expected in Q4 2026.
- The XanaCIDD Phase 2a trial for major depressive disorder showed significant benefits on depression symptoms.
- Xanamem, the lead compound, is being developed to control brain cortisol levels and is investigated for Alzheimer's disease and depression.
- Actinogen completed an $11.1 million capital raising and received a $9 million R&D tax incentive rebate.
- The company conducted commercial readiness planning, including appointing a Chief Commercial Officer and securing a manufacturing scale-up.
- The FY2025 net loss was $14,732,263, primarily due to R&D expenses for clinical trials.
- Upcoming news includes interim data from the XanaMIA trial and potential FDA and EMA interactions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
ACW Appendix 4E and 2025 annual report
|
25 Aug 2025 6:42PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical focuses on therapies for neurological diseases.
- The company reported a net loss of $14.7 million for FY2025.
- Revenue from ordinary activities increased by 135% to $685,253.
- Clinical trials for Xanamem, targeting Alzheimer's and Depression, are underway.
- The XanaMIA phase 2b/3 trial is a crucial part of their clinical program.
- Interim results for the Alzheimer's trial are expected in January 2026.
- Actinogen Medical is financially stable and actively pursuing strategic collaborations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$145 |
ACW Appendix 4E and 2025 annual report
|
25 Aug 2025 6:42PM |
$0.029 |
$0.039 |
risen by
36.84%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited's financial report covers the fiscal year ending 30 June 2025.
- The company had cash and cash equivalents totaling $15,718,435 at the end of the fiscal year.
- The total financial liabilities amounted to $1,498,495.
- Interest rate risk is managed by assessing potential changes in interest rates and their impact.
- The exercise of unlisted and listed options contributed to changes in issued shares.
- Various share issues and cancellations occurred during the year for both employee and director loan plans.
- Total current liabilities were $1,240,099, with non-current liabilities at $258,396.
- A sensitivity analysis model was used to assess the impact of interest rate fluctuations on profit/equity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,110 |
GYG Confirmation of Voluntary Escrow Release
|
25 Aug 2025 6:39PM |
$25.540 |
$21.200 |
fallen by
16.99%
|
|
| Platinum Asia Investments Limited (PAI) ORDINARY FULLY PAID |
Financials |
- |
Implementation of Scheme and Delisting
|
25 Aug 2025 6:36PM |
$0.970 |
$0.970 |
fallen by
0%
|
|
| New Frontier Minerals Limited (NFM) ORDINARY FULLY PAID |
Materials |
$10 |
Notification regarding unquoted securities - NFM
|
25 Aug 2025 6:34PM |
$0.013 |
$0.006 |
fallen by
53.85%
|
|
| Flagship Minerals Limited (FLG) ORDINARY FULLY PAID |
Materials |
$60 |
Application for quotation of securities - FLG
|
25 Aug 2025 6:34PM |
$0.060 |
$0.175 |
risen by
191.67%
|
|
| Goodman Group (GMG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$61,180 |
30 June 2025 Distribution Taxation Components
|
25 Aug 2025 6:29PM |
$34.190 |
$29.920 |
fallen by
12.49%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$14 |
Change in substantial holding
|
25 Aug 2025 6:26PM |
$0.044 |
$0.028 |
fallen by
36.36%
|
|
| Great Northern Minerals Limited (GNM) ORDINARY FULLY PAID |
Materials |
$16 |
Ceasing to be a substantial holder
|
25 Aug 2025 6:19PM |
$0.082 |
$0.033 |
fallen by
59.76%
|
|
| Step One Clothing Limited (STP) ORDINARY FULLY PAID |
Consumer Discretionary |
$25 |
Change of Director's Interest Notice - David Gallop
|
25 Aug 2025 6:12PM |
$0.570 |
$0.135 |
fallen by
76.32%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$11,089 |
Change in substantial holding
|
25 Aug 2025 6:11PM |
$31.800 |
$34.850 |
risen by
9.59%
|
|
| Almonty Industries Inc (AII) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$51 |
Cleansing Statement
|
25 Aug 2025 6:10PM |
$6.620 |
$21.650 |
risen by
227.04%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$14 |
Cleansing Notice
|
25 Aug 2025 6:10PM |
$0.044 |
$0.028 |
fallen by
36.36%
|
|
| Almonty Industries Inc (AII) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$51 |
Notification regarding unquoted securities - AII
|
25 Aug 2025 6:09PM |
$6.620 |
$21.650 |
risen by
227.04%
|
|
| Magmatic Resources Limited (MAG) ORDINARY FULLY PAID |
Materials |
$14 |
Notification regarding unquoted securities - MAG
|
25 Aug 2025 6:08PM |
$0.044 |
$0.028 |
fallen by
36.36%
|
|
| St Barbara Limited (SBM) ORDINARY FULLY PAID |
Materials |
$557 |
Change of Director's Interest Notice
|
25 Aug 2025 6:07PM |
$0.345 |
$0.460 |
risen by
33.33%
|
|
Call 1300 880 160
Start a chat
Schedule a call
